{
“title”: “=NRG-GY028 Trial Explores Endometrial Cancer Treatment”,
“content”: “=\n
A new clinical trial from NRG Oncology, known as NRG-GY028, has opened for patients with advanced-stage or recurrent endometrial cancer. The study will examine how lenvatinib and pembrolizumab, a common treatment combination, affect the immune system when taken before undergoing standard treatment for this type of cancer.
The goal is to better understand how this drug combination engages the immune system to attack tumors. “We want to go beyond the current statistics and understand how these treatments work on a cellular level. This could explain why some patients respond better than others,” said Dr. Haider Mahdi, the study’s principal investigator and a gynecologic oncologist at the University of Pittsburgh Medical Center.
Participants will first receive lenvatinib and pembrolizumab before starting the usual treatment. Researchers will then examine changes in immune cells and tissue samples to measure the biological response. This could help develop better strategies for selecting treatments in the future.
“We are not just conducting a clinical trial; we are trying to drive innovation in personalized medicine for endometrial cancer,” added Dr. Mahdi.
The study is now accepting patients at approved clinical sites across the United States.
“,
“status”: “draft”,
“categories”: “=1”,
“featured_media”: “=”
}
